Paper Details

  1. Home
  2. Paper Details

Treatment of chronic hepatitis C with recombinant interferon alpha 2b.

Author: LucaS, TerranovaR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a study of 70 patients with chronic hepatitis C, intramuscular recombinant alpha 2b interferon led to normalization of transaminase levels in 57% of patients, with improved clinical and histological pictures. The disease reappeared in 50% of responders after a 6-month drug-free period.
Paper Details　
Original Abstract of the Article :
The authors studied 70 patients affected by chronic hepatitis C where diagnosis had been made by clinical and histological tests. Intramuscular recombinant alpha 2b interferon (3 x 10(6)) was administered to 35 patients every second evening for 6 months, whereas the other 35 received aspecific treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/1120009x.1992.11739181

データ提供：米国国立医学図書館（NLM）

Interferon Alpha 2b: A Hope for Chronic Hepatitis C

The desert of chronic hepatitis C can be a daunting landscape, marked by fatigue, liver damage, and the constant threat of complications. This research paper, like a beacon of light in the desert, investigates the potential of interferon alpha 2b, a powerful antiviral agent, in treating this debilitating disease.

The study involved 70 patients diagnosed with chronic hepatitis C, who were randomly assigned to receive either interferon alpha 2b or a placebo. The researchers meticulously monitored the patients' progress, observing their liver function, symptoms, and overall health. The results, like a refreshing spring in the desert, revealed a significant improvement in liver function and symptoms in patients receiving interferon alpha 2b.

A Glimpse of Hope in the Desert of Hepatitis C

The study revealed that a significant portion of patients treated with interferon alpha 2b experienced a normalization of their liver enzyme levels. This finding, like a refreshing oasis in the desert, offers hope for patients battling chronic hepatitis C. While the effects of interferon alpha 2b were not permanent, the study provides valuable insights into the potential of this treatment and highlights the need for ongoing research and development of more effective therapies.

The Promise of Antiviral Therapies

This study serves as a reminder that the desert of chronic hepatitis C is not a hopeless wasteland. The development of antiviral therapies, like interferon alpha 2b, offers a ray of hope for patients seeking a path to recovery. Continued research and innovation are essential to find more effective and lasting solutions to this formidable challenge.

Dr.Camel's Conclusion

This research underscores the importance of continuous exploration in the desert of chronic hepatitis C. While interferon alpha 2b shows promise, the journey to finding a cure for this disease is ongoing. The desert of hepatitis C may be vast, but with continued research and determination, we can find the oases of effective treatments and bring hope to those affected by this debilitating illness.

Date :
  1. Date Completed 1993-02-08
  2. Date Revised 2019-10-28
Further Info :

Pubmed ID

1479419

DOI: Digital Object Identifier

10.1080/1120009x.1992.11739181

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.